GoodRx expands access to Eli Lilly’s new oral GLP-1 Foundayo

GoodRx (GDRX) announced that it is working with Eli Lilly and Company (LLY) to expand access to the newly FDA-approved oral GLP-1 medication, Foundayo. Eligible self-pay patients can access Foundayo through GoodRx at a starting price of $149 per month, in line with the lowest available discounted cash price at launch. The offering provides transparent pricing and nationwide pharmacy access for the highly anticipated weight management treatment. GoodRx is also expanding access to Zepbound KwikPen, available to eligible self-pay patients starting at $299 per month at more than 70,000 pharmacies nationwide. Together with the launch of Foundayo, these offerings expand access to both oral and injectable GLP-1 treatments for adults seeking prescribed obesity care outside traditional insurance pathways.